Cempra - solithromycin (CEM-101) for civilian use and broad bioterror threat medical countermeasures.

Ended Definitive Contract Awarded Last action

Contract number
HHSO100201300009C
Awardee
Awarding agency
Obligated
$52,487,981

Award facts

Contract value 80% obligated
  • $52,487,981.21 Current, with exercised options
  • $65,746,932.93 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Chapel Hill, NC, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00031 -$15,287,831
Other Administrative Action P00030 -$89,005
Other Administrative Action 29 -$361,717
Other Administrative Action 28 $0
Other Administrative Action 27 $0
Other Administrative Action 26 $0
Other Administrative Action 25 $0
Other Administrative Action 24 $0
Other Administrative Action 23 $0
Other Administrative Action 22 $0
Other Administrative Action 21 $0
Other Administrative Action 20 $0
Other Administrative Action 19 $0
Other Administrative Action 18 $0
Other Administrative Action 17 $8,000,000
Other Administrative Action 16 $0
Exercise an Option 15 $25,521,725
Other Administrative Action 14 $0
Other Administrative Action 13 $0
Other Administrative Action 12 $0
Other Administrative Action 11 $0
Other Administrative Action 10 $424,115
Other Administrative Action 9 $0
Other Administrative Action 8 $0
Other Administrative Action 7 $0
Other Administrative Action 6 $0
Exercise an Option 5 $15,999,772
Exercise an Option 4 $0
Exercise an Option 3 $0
Other Administrative Action 2 $570,495
Other Administrative Action 1 $0
Original award $17,710,427
Show all 32

About this award

Written by GovTribe AI ·

This is a $65,746,932.93 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Cempra Pharmaceuticals, Inc., a subsidiary of Melinta Therapeutics, LLC. The contract is for the development of SOLITHROMYCIN (CEM-101) for civilian use and as a broad bioterror threat medical countermeasure. The contract has an ultimate completion date of October 31, 2018 and was awarded on May 24, 2013. The contract is not set aside.

Quick answers

Who was awarded contract HHSO100201300009C?

HHSO100201300009C was awarded to Cempra Pharmaceuticals, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on May 24, 2013.

How much is contract HHSO100201300009C worth?

The government has obligated $52,487,981 on HHSO100201300009C. Its potential value, with all options, is $65,746,933.

Was contract HHSO100201300009C competed?

The extent of competition for HHSO100201300009C was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login